

Collaboration Agreement Patient Organisation

between

Bayer A/S
Company registration number (CVR) 16 08 98 18
Arne Jacobsens Allé 13, 6.
2300 København S
Denmark
(**"Bayer"**)

and

Danmarks Bløderforening
c/o Karen Binger Holm
Kompagnistræde 22, 2. sal baghuset
1208 København K
CVR-nr: 11802990
(**"Organisation"**)

Bayer and Organisation jointly referred to as "Parties".

Hereby the Parties agree as follows:

1. Project description

Organisation is active in the field of Hemophilia. Bayer is active in the field of Hemophilia. The Parties have agreed to collaborate on sponsoring one participant to an event named:

"Nordiskt möte 15-17. November 2019, Copenhagen"

The purpose of the collaboration: There is strong solidarity and tradition in the international bleeding community for sharing knowledge and experience about life with bleeding disease. International research is crucial for the development and optimization of bleeding treatment, also in Denmark. International meetings and conferences are important arenas for gaining new knowledge and building relationships, and therefore the Danish Society of Diseases prioritizes participation. It is important for Bayer to gain insight into how "Danmarks Bløderforening" and patients are looking at above from a patient perspective.

The project is set out to be conducted in accordance with relevant laws and regulations including, but not limited to, the Ethical rules for Collaboration with Patient Groups etc. (Patientforeningskodeks) effective from 1/1- 2017, until further notice.

Activity: "Nordiskt möte"
Subject: Hemophilia/Bleeding disorders
Date: November 15-17 2019
Place: Copenhagen
Venue: Admiral Hotel

2. Parties obligations

- 2.1. Bayer shall cover travel, hotel accommodation, conference room, catering (NOT dinner and entry at Tivoli) and honorar to speaker, and workshop. Details in budget summary attached.
- 2.2. The Organisation shall arrange the entire meeting and book conference room, travel and hotel accommodation. Deliverables for Bayer: Two Bayer free participation during programme on Saturday 16th Nov. (NO dinner participation – only during day-agenda). Bayer-logo in invitation and programme. After the end of the meeting provide Bayer with a written report with their experience from the meeting. For example, important data / treatment guidelines for Hemophilia. (Report completed and reported to Bayer latest December 31, 2019).

3. Finance

- 3.1. Bayer has committed to finance the Project with the amount of max DK 27.782 (Twenty seven thousand seven hundred and eighty two Danish Kroner). Bayer's finance is to support travel, hotel accommodation, conference room, catering (NOT dinner and entry at Tivoli), honorar to speaker, and workshop. The costs necessary for conduct of the scientific and professional parts of the Project. The finance shall not be used for other costs such as; social activities, costs for ordinary business, internal activities or otherwise in conflict with applicable laws and regulations.
- 3.2. The Organisation has committed to finance the project with the amount of DK 287.230 (Two hundred and eighty seven thousand two hundred and thirty Danish Kroner.)

Any payments made by Bayer will be upon receipt of a proper invoice (to be issued in the name and on the letterhead of the Organisation) including reference- Purchase Order number and which meets all requirements according to applicable VAT requirements. Bayer shall pay within 45 days from receipt of the correct invoice.

- 3.2. Payment will be administrated and invoiced by the Organisation to Bayer on the following address.

Invoice address:

Bayer A/S
c/o Invoice reception point
D-51368 Leverkusen
Germany

Reference: PO number, will be communicated from Bayer via e-mail.

4. Transparency

- 4.1. The Parties agree that the content of this agreement can at any time be disclosed to a third party on request.
- 4.2. The parties agree that Bayer will upload the content of this Agreement on their website no later than project start and have it published until at least six months after the collaboration has ended.
- 4.3. The Parties declare that this Agreement is not in any way associated with any business or sales activities between the Parties hereto and in particular Organisation is by no means obligated to prescribe, recommend or purchase any goods from Bayer.
- 4.4. The parties agree that Bayer will at the end of each calendar year submit information regarding the collaboration to LIF in accordance with the applicable ethical rules.
- 4.5. The Parties warrant that the collaboration subject to this Agreement is in no way associated with influencing the Organisations opinions on professional and political issues.
- 4.6. The Parties declare that this Agreement is not in any way associated with any business or sales activities between the Parties hereto and in particular Organisation is by no means obligated to prescribe, recommend or purchase any goods from Bayer.
- 4.7. Bayer warrants that it does not hold any position within the organisation which might cause any unethical conflicts of interest for the purpose of this Agreement.

5. Contact

- 5.1. Bayer has appointed cecilia.berndt@bayer.com +46708825320 as contact person for enquires regarding this Agreement.
- 5.2. Organisation has appointed Karen Binger Holm, kbh@bloderforeningen.dk +45 33 14 55 05 as a contact person for enquiries relating to this Agreement

6. Usage of Logo- intellectual property trademark etc.

The parties should not use each other's logos without a prior written consent. When acquiring such consent, the requesting Party shall state for which specific purposes and in which way the logo and name shall be used.

7. Term

Duration of the project is November 15-17, 2019.

This contract comes into force upon signature of both Parties and continues until 191231.

8. Termination

If either Party is in breach or default in the performance of its obligations under this Agreement, and such breach or default continues for thirty (30) days after written notice by the other Party, may the non-breaching or non-defaulting Party have the right to terminate the Agreement with immediate effect.

9. Adverse Event/Product Technical Complaint

Under EU legislation Bayer and its contracted partners are obliged to fulfil certain Pharmacovigilance responsibilities stated in the Good Pharmacovigilance Practice (GVP) and relevant guidelines. Therefore Organisation agrees to provide to Bayer written reports of all Adverse Events, Product Technical Complaints regarding Bayer product(s) and service(s) covered by this Agreement that come to their attention by fax (+46 8 580 224 02) or e-mail (drugsafety.scand@bayer.com) within one (1) business day from receipt of information.

All known cases of exposure during pregnancy (including paternal exposure) and breastfeeding, misuse, abuse, lack of drug effect, overdose (accidental and intentional), medication error/use error, drug dependency, suspected transmission of an infectious agent, withdrawal syndrome, drug interactions, occupational exposure, off-label use, or unexpected Product benefit with respect to the Product(s) must be reported in the same manner as an Adverse Event /Product Technical Complaint.

For the purposes of this Agreement, an "Adverse Event" shall mean any untoward medical occurrence in a patient administered the Bayer product, which does not necessarily have to have a causal relationship with this treatment. A "Product Technical Complaint" is any report (written, electronic or verbal communication) about a potential or alleged failure of the Bayer product in its quality (including the identity, durability, reliability, safety, efficacy or performance) or suspected counterfeit. The complaint may or may not represent a potential risk to the patient.

10. Miscellaneous

- 10.1. This Agreement contains the entire agreement between the Parties. Any amendments to this Agreement shall be made in writing and duly signed by the Parties. If any provision of this Agreement is or becomes invalid or unenforceable, shall this not affect the remaining provisions hereof. The Parties shall in this case replace the invalid or unenforceable provision with a provision that is as close as possible to the economic effect of the invalid or unenforceable provision.
- 10.2. This Agreement shall be construed, controlled and interpreted by the Laws of Denmark. The Parties agree to the exclusive jurisdiction of the Copenhagen District Court as first instance.

This Agreement has been executed in two (2) copies, with each party receiving one (1) copy.

COPENHAGEN 5/11-2019
(Place) (Date)

ORGANISATION

Danmarks Bløderforening

Karen B. H.
Signature

CEO
Clarification of signature, title

Solna 04/11/2019
(Place) (Date)
BAYER A/S

Solna 19/11/04
(Place) (Date)
BAYER A/S

Cecilia Berndt
Signature

Cecilia Berndt
Business Area Manager, Scandinavia

Catharina Linder
Signature

Catharina Linder
Sales & Marketing Assistant, Scandinavia



Bayer

Den 31. oktober 2019

Ansøgning om støtte til Nordisk møde i København d. 15-17. november 2019

For patienter med sjældne sygdomme som blødersygdomme er det helt afgørende, at viden og erfaringer om både behandling og livskvalitet kan deles på tværs af landegrænser. Med denne ansøgning søger Danmarks Bløderforening om støtte til afholdelse af det årlige møde for bløderforeninger i Norden. I år inviteres også repræsentanter fra bløderforeninger i Estland, Letland og Litauen til at deltage.

Mødet afholdes d. 15-17. november 2019 på Hotel Admiral i København. Udover foreningsrepræsentanter inviteres også unge-repræsentanter fra de nordiske lande. Danske bløderlæger og sygeplejersker og repræsentanter fra medicinalindustrien inviteres også til at deltage i en del af mødet.

Fredag er der fokus på erfaringsudveksling og "good practice" blandt bløderforeningerne. Lørdag og søndag er programmet opdelt i tre spor: Et fælles spor med fokus på adhærens og senfølger af blødersygdom, et spor for foreninger med fokus på "comprehensive care" og et ungespor med fokus på engagement og motivering af andre unge. Se vedlagte program.

Med flere behandlingsmuligheder til rådighed tydeliggøres behovet for højt specialiserede hæmofilicentre, der har kapacitet til at håndtere både behandling og kvalitetssikring. Bløderne bliver samtidig ældre og får i stigende grad samme livsstils- og aldersrelaterede sygdomme som resten af befolkningen. Derfor er der brug for "comprehensive care" centre, der også kan koordinere blødernes behandling i samarbejde med andre specialer og omsorgspersoner. I Sverige, Norge, Finland og Litauen er der certificerede EHCC centre og Estland har et certificeret EHT center. Der er endnu ikke certificerede centre i Danmark, Island og Letland, jf. EUHANET standarderne.

Det samlede budget for mødet er i alt 287.230 kr. Der søges om støtte fra Bayer på 27.782 kr. Se vedlagte budget.

Der inviteres to repræsentanter fra hvert medicinalfirma med produkter i markedet til at deltage i lørdagens program – fælles spor og foreningsspor – samt middag lørdag i Tivoli. Ved støtte vil firmalogo fremgå af endelig invitation og program.

Al støtte til dette formål er velkommen og modtages med tak. Hvis der er spørgsmål til ansøgningen, må I endelig kontakte mig.

Venlig hilsen

Karen Binger Holm

Sekretariatsleder, Danmarks Bløderforening

Program for the Nordic Meeting 2019

Date: Saturday the 16th of November

Host: The Danish Haemophilia Society

Venue: Admiral Hotel, Toldbodgade 24-28, 1253 Copenhagen

Participants: Representatives and youth representatives from haemophilia societies in Sweden, Norway, Finland, Island and Denmark, Estonia, Latvia, Lithuania – and guests from EAHAD, the pharma industry and Danish haemophilia centers.

Saturday the 16th of November

10.00-10.15 Opening and welcome

10.15-11.15 Joint status, QoL and the Tarzan Syndrome among hemophiliacs 30+

Presentation on:

- Danish research on joint status and QoL (tbc)
- Tarzan Syndrome in the Clinic by Chief Physician Peter Kampmann, The Royal Hospital of Copenhagen
- Network for people with bleeding disorder 30+ and the challenges of the group by Jacob Bech Andersen, chairman of the Danish Haemophilia Society

11.15-11.30 Break

11.30- 12.30 Presentation of the MIND Study – Management of Health Related QoL Impairment, Including, Pain, Depression, and Anxiety, in Patients with Haemophilia A and B by the Swedish Institute for Health Economics (IHE)

12.30-13.30 Lunch

13.30-14.30 The work of EUHANET and status of European Hemophilia Comprehensive Care (EHCC) Centers by Aislin Ryan, CEO, European Association for Haemophilia and Allied Disorders, EAHAD

14.30-15.00 Break

15.00-16.00 Discussion about future needs for Comprehensive Care in Haemophilia from different perspectives

- Danish haemophilia patient
- Danish haemophilia doctor
- Representative from the Danish Health Authority (tbc)
- Representative from EAHAD
- Representative from Lif (tbc)

16.00-16.30 Wrap up and group photo

18.00 Dinner

Thank you to our sponsors Bayer, CSL Behring, The European Haemophilia Consortium (EHC), Novo Nordisk, Octapharma, Pfizer, Roche, Sobi and Takeda for supporting the Nordic Meeting 2019 in Copenhagen.

Budget Nordisk Møde 2019 (DKK)

Deltagere:

40 personer deltager i hele arrangementet Nordisk Møde fra 15 november-17 november

- To foreningsrepræsentanter og to ungerepræsentanter fra bløderforeninger i Sverige, Norge, Finland og Island (16)
- To foreningsrepræsentanter bløderforeninger i Estland, Letland og Litauen (6)
- 11 medlemmer af Danmarks Bløderforenings bestyrelse (11)
- To danske ungerepræsentanter (2)
- Tre medarbejdere fra Danmarks Bløderforenings sekretariat (3)
- En repræsentant fra EAHAD og en repræsentant fra EHC (2)

27 personer deltager i dagprogrammet lørdag d. 16 november

- De otte medicinalfirmaer, som har produkter på markedet til bløderpatienter er inviteret med to repræsentanter hver (16)
- To hæmofililæger og to hæmofilisygeplejersker fra de to højt specialiserede behandlingscentre ved hhv. Rigshospitalet og Aarhus Universitetshospital inviteres til at deltage (8)
- Oplægsholdere: Katarina Steen Carlsson - IHE, Peter Kampmann - Hæmofilicenter Rigshospitalet, DeltagerDanmark (3)

	Detaljer	DBF	Ansøgt beløb 222.260 / 8 = 27.782
Rejseudgifter		kr. 8.500	kr. 4.000
Rejseudgifter for Danmarks Bløderforenings bestyrelsesmedlemmer	Gennemsnitlig transportudgift estimeres til 500. kr. Der er 11 bestyrelsesmedlemmer.	kr. 5.500	
Taxa til Tivoli	56 personer transporteret fra Hotel Admiralen til Tivoli. Ca. 2 kr.	kr. 3.000	
Transport - EAHAD repræsentant og EHC repræsentant	To personer København - Bruxelles tur/retur á 1.500 kr. Metro/taxa		kr. 3.000 kr. 1.000
Overnatningsudgifter			kr. 76.000
Overnatning to dage	To dages overnatning på Hotel Admiralen. Pris pr. nat 950 kr. (40 personer)		kr. 76.000
Mødelokaler mv.			kr. 10.000
Et mødelokale på Hotel Admiralen lørdag og søndag	5.000 kr. pr. dag		kr. 10.000
Forplejning		kr. 28.000	kr. 107.260
Mødeforplejning fredag	Forplejning á 595 kr. pr. deltager/40 personer		kr. 23.800
Mødeforplejning lørdag	Forplejning á 780 kr. pr. deltager/67 personer		kr. 52.260
Mødeforplejning søndag	Forplejning af 780 kr. pr. deltager/40 personer		kr. 31.200
Middag i Tivoli	Estimeret pris 500 kr. pr. person/56 deltagere	kr. 28.000	
Services		kr. 28.470	kr. 25.000
Oplæg v. overlæge Peter Kampmann	Honorar á 5.000 kr.		kr. 5.000
Gaver til oplægsholdere	Gaver til oplægsholdere á 250 kr./12 stk	kr. 3.000	
Workshop v. DeltagerDanmark	Tre timers workshop for unge blødere om at etablere og engagere flere i frivilligt dreven		kr. 20.000
Indgang til Tivoli	Indgang á 90 kr./56 personer	kr. 5.040	
Sekretariatsudgifter	Projektstyring i Danmarks Bløderforenings sekretariat Projektmedarbejder (45 timer af 194 kr/t) og sekretariatsleder (30 timer af 390 kr./t)	kr. 20.430	
TOTAL		kr. 64.970	kr. 222.260